Raycat
Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy.
The vaccine for extraintestinal pathogenic E. coli is being jointly developed by Sanofi